Palatin Technologies (PTN) EBT Margin (2010 - 2026)

Palatin Technologies' (PTN) quarterly EBT Margin came in at 36.55% in Q1 2026, up 99.42% on a QoQ basis from 6260.01% in Q4 2025.

Palatin Technologies (PTN) EBT Margin (2010 - 2026) Analysis & Trends

Palatin Technologies (PTN) has 14 years of EBT Margin data on file, last reported at 36.55% in Q1 2026.

Quarterly EBT Margin changed N/A year-over-year to 36.55% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 48.69% (up 661332.0% YoY) and the FY2024 annual result came in at 662.26%, down 7035.0% from the prior year.
EBT Margin rose to 36.55% in Q1 2026, from 6260.01% in the prior quarter.
In the past five years, EBT Margin ranged from a high of 52.97% in Q3 2025 to a low of 6260.01% in Q4 2025.
A 5-year average of 1477.45% and a median of 641.66% in 2023 frame the typical range for EBT Margin.
Annual changes were most pronounced in 2022 — EBT Margin soared 561247 bps — and 2024, when it plunged 179900 bps.
Tracing PTN's EBT Margin over 5 years: stood at 191.69% in 2022, then plunged by 101 bps to 385.62% in 2023, then sank by 511 bps to 2357.27% in 2024, then tumbled by 166 bps to 6260.01% in 2025, then jumped by 99 bps to 36.55% in 2026.
The last three EBT Margin figures came in at 36.55% (Q1 2026), 6260.01% (Q4 2025), and 52.97% (Q3 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	35.61%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	35.71%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-528.97%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	18.33%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	13.77%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-2.67%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	12.09%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-25.06%
10	Palatin Technologies	40.86 Mn	40.86 Mn	-	-36.55%

Download Data